PepGen Proposes $125 Million Stock and Warrant Offering

PepGen Inc. (Nasdaq: PEPG) proposed a $125 million public offering of common stock and pre-funded warrants, with net proceeds intended for clinical development and other corporate needs.

PepGen plans to give underwriters a 30-day option to purchase up to $18.75 million in additional shares. The proposed offering is subject to conditions and may not be completed. Net proceeds would support clinical development, working capital and other general corporate purposes.

The financing proposal comes as PepGen’s FREEDOM2-DM1 study remains under a partial clinical hold in the United States. As of Nov. 10, no U.S. participants had been dosed. The company expects results from the fully enrolled 12.5 mg/kg cohort in the first half of 2027.

Interim data from the FREEDOM-OLE open-label extension study are expected in January 2027. The update is expected to include clinical data at 5 mg/kg and safety data at 10 mg/kg. PepGen’s earlier Phase 2 results in myotonic dystrophy provide background on its clinical program.